- Search for Research Summaries, Reviews, and Reports
- EPC Project
Related Products for this Topic
- Executive Summary Nov. 1, 2007
Research Review - Final – Nov. 1, 2007
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension
- Final Report (PDF) 375 kB
- Report Appendixes (PDF) 1.2 MB
- Web Version (NLM Site)
- Help with Viewers, Players, and Plug-ins
People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.
Archived: This report has been updated.
In this comparative effectiveness review, we examine the scientific literature on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs, or angiotensin receptor blockers) for individuals with hypertension regarding their relative benefits (blood pressure control, cardiovascular risk reduction, cardiovascular events, quality of life, and other outcomes), as well as relative risks (safety, adverse events, tolerability, persistence, and adherence). In addition, we will examine the clinical determinants of these outcomes with a focus on the long-term impact.